SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.80

25 Jun
2026

0.070

OPEN

$2.74

2.56%

HIGH

$2.81

25,697,475

LOW

$2.74

TARGET
$3.286 17.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP . SK1 .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 6.2 7.3 xxx
DPS (cps) xxx 4.0 4.7 xxx
EPS Growth xxx 21.9% 18.0% xxx
DPS Growth xxx 100.0% 17.5% xxx
PE Ratio xxx N/A 35.6 xxx
Dividend Yield xxx N/A 1.8% xxx
Div Pay Ratio(%) xxx 64.8% 64.5% xxx

Dividend yield today if purchased 3 years ago: 5.19%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.54

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 2.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx6.2
DPS All xxxxxxxxxxxxxxx4.0
Sales/Revenue xxxxxxxxxxxxxxx10,835.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.4
Net Operating Cash Flow xxxxxxxxxxxxxxx575.6 M
Net Profit Margin xxxxxxxxxxxxxxx6.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx14.67 %
Return on Invested Capital xxxxxxxxxxxxxxx10.62 %
Return on Assets xxxxxxxxxxxxxxx7.86 %
Return on Equity xxxxxxxxxxxxxxx14.67 %
Return on Total Capital xxxxxxxxxxxxxxx14.52 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx140.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx208 M
Long Term Debt xxxxxxxxxxxxxxx1,813 M
Total Debt xxxxxxxxxxxxxxx2,021 M
Goodwill - Gross xxxxxxxxxxxxxxx3,626 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx131 M
Price To Book Value xxxxxxxxxxxxxxx6.33

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx56.7 M
Capex % of Sales xxxxxxxxxxxxxxx0.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx8,878 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx959 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx114 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

06/05/2026

1

Buy

$3.40

21.43%

Ord Minnett found several positives in the trading update from Sigma Healthcare including the Australian Chemist Warehouse store sales in the year to date increasing 16.7% with international up 24.7%.

The broker also welcomed the MOU with Greenlight Healthcare that will mean Chemist Warehouse enters the UK market. Greenlight has 22 stores across Greater London with phase 1 of the agreement to focus on five initial stores and Sigma set to acquire a 75% interest in each.

The company has also appeared to entrench its dominance in New Zealand. Ord Minnett retains a Buy rating and raises the target to $3.40 from $3.30.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 3.90 cents and EPS of 6.50 cents.
Ord Minnett forecasts a full year FY27 dividend of 4.70 cents and EPS of 7.80 cents.

Morgans

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

07/05/2026

1

Buy

$3.60

28.57%

Jarden reiterates its Buy rating and $3.60 target price for Sigma Healthcare after the company reported accelerating top-line sales growth and announced a capital-light entry into the UK market.

Domestic momentum remained strong through the second half, with Chemist Warehouse (AU) sales growth picking up to 17.1% year-on-year in March and April due to store expansions, share gains, and structural health tailwinds.

The broker views the new 75% joint venture with London-based GreenLight Pharmacy as a sensible expansion strategy, providing immediate access to 22 locations and existing licenses with zero initial equity cost.

This allows the company to deploy its Every Day Low Price (EDLP) and multi-buy model into an under-penetrated market where competitors currently charge premiums.

Earnings forecasts are maintained, though the broker notes modest upside risk to margin expectations as the company scales its operations and integrates its newly announced $40m New Zealand distribution centre.

FORECAST
Jarden forecasts a full year FY26 dividend of 3.80 cents and EPS of 6.40 cents.
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

Latest Health & Nutrition News

1
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
2
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
3
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
4
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
5
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
6
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
7
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
8
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
9
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
10
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia